99 related articles for article (PubMed ID: 38473207)
1. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
2. TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha.
Romo BA; Karakyriakou B; Cressey L; Brauer BL; Yang H; Warren A; Johnson AL; Kettenbach AN; Miller TW
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473207
[TBL] [Abstract][Full Text] [Related]
3. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of ZBTB7A inhibits cell proliferation of breast cancer through regulating the ubiquitination of estrogen receptor alpha.
Xiao X; Shen Y; Yin L; He J; Ni X; Luo G; Chen X; Zhu W; Zhong J; Liu J; Peng X; Zu X
Life Sci; 2019 Dec; 239():117042. PubMed ID: 31715186
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
6. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
7. TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression.
Zhuang T; Wang B; Tan X; Wu L; Li X; Li Z; Cai Y; Fan R; Yang X; Zhang C; Xia Y; Niu Z; Liu B; Cao Q; Ding Y; Zhou Z; Huang Q; Yang H
Cell Commun Signal; 2022 Apr; 20(1):45. PubMed ID: 35392925
[TBL] [Abstract][Full Text] [Related]
8. Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Traphagen NA; Schwartz GN; Tau S; Roberts AM; Jiang A; Hosford SR; Marotti JD; Goen AE; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
Clin Cancer Res; 2023 Sep; 29(18):3717-3728. PubMed ID: 37439680
[TBL] [Abstract][Full Text] [Related]
9. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer.
Győrffy B
Geroscience; 2023 Jun; 45(3):1889-1898. PubMed ID: 36856946
[TBL] [Abstract][Full Text] [Related]
10. Cancer statistics, 2023.
Siegel RL; Miller KD; Wagle NS; Jemal A
CA Cancer J Clin; 2023 Jan; 73(1):17-48. PubMed ID: 36633525
[TBL] [Abstract][Full Text] [Related]
11. TRIM proteins in breast cancer: Function and mechanism.
Bai X; Tang J
Biochem Biophys Res Commun; 2023 Jan; 640():26-31. PubMed ID: 36495607
[TBL] [Abstract][Full Text] [Related]
12. TurboID functions as an efficient biotin ligase for BioID applications in Xenopus embryos.
Kanzler CR; Donohue M; Dowdle ME; Sheets MD
Dev Biol; 2022 Dec; 492():133-138. PubMed ID: 36270327
[TBL] [Abstract][Full Text] [Related]
13. Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1.
Luciano AK; Korobkina ED; Lyons SP; Haley JA; Fluharty SM; Jung SM; Kettenbach AN; Guertin DA
J Biol Chem; 2022 Oct; 298(10):102379. PubMed ID: 35973513
[TBL] [Abstract][Full Text] [Related]
14. TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.
Chen M; Lingadahalli S; Narwade N; Lei KMK; Liu S; Zhao Z; Zheng Y; Lu Q; Tang AHN; Poon TCW; Cheung E
EMBO Rep; 2022 Aug; 23(8):e53468. PubMed ID: 35785414
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
